T he vast majority of cancer-related deaths that occur are due to metastasis 1, 2 . Lethality from metastasis can be attributed to two distinct factors. First, the invasion and growth of metastatic cancer cells within different organs can disrupt their normal physiological functions. Second, metastatic tumors release soluble proteins, exosomes and metabolites [3] [4] [5] that can systemically affect organs that are otherwise free of cancer. For instance, cancer cells rarely metastasize to skeletal muscle, but tumor-secreted factors induce extensive muscle wasting 3 , resulting in a syndrome known as cachexia 6, 7 . Patients with cancer cachexia often become too weak to tolerate standard doses of anticancer therapies, and those with wasting of diaphragm and cardiac muscles often die prematurely because of respiratory and cardiac failure 6, 8 . Notably, cachexia shortens the survival of patients with cancer, and there are no approved drugs that can effectively alleviate this condition 9 . A characteristic feature of cancer cachexia is a reduction in muscle size, also known as muscle atrophy. This is a process characterized by marked deterioration of cellular organelles, cytoplasm and proteins in muscles 10, 11 . Indeed, enhanced breakdown of muscle proteins, often accompanied by decreased synthesis, contributes to the altered muscle homeostasis and muscle mass loss in cancer cachexia 6 . Although cachexia is a key indicator of poor prognosis in patients with cancer, the mechanisms underlying muscle wasting remain poorly understood.
T he vast majority of cancer-related deaths that occur are due to metastasis 1, 2 . Lethality from metastasis can be attributed to two distinct factors. First, the invasion and growth of metastatic cancer cells within different organs can disrupt their normal physiological functions. Second, metastatic tumors release soluble proteins, exosomes and metabolites [3] [4] [5] that can systemically affect organs that are otherwise free of cancer. For instance, cancer cells rarely metastasize to skeletal muscle, but tumor-secreted factors induce extensive muscle wasting 3 , resulting in a syndrome known as cachexia 6, 7 . Patients with cancer cachexia often become too weak to tolerate standard doses of anticancer therapies, and those with wasting of diaphragm and cardiac muscles often die prematurely because of respiratory and cardiac failure 6, 8 . Notably, cachexia shortens the survival of patients with cancer, and there are no approved drugs that can effectively alleviate this condition 9 . A characteristic feature of cancer cachexia is a reduction in muscle size, also known as muscle atrophy. This is a process characterized by marked deterioration of cellular organelles, cytoplasm and proteins in muscles 10, 11 . Indeed, enhanced breakdown of muscle proteins, often accompanied by decreased synthesis, contributes to the altered muscle homeostasis and muscle mass loss in cancer cachexia 6 . Although cachexia is a key indicator of poor prognosis in patients with cancer, the mechanisms underlying muscle wasting remain poorly understood.
Cachexia is predominantly observed in patients with advanced cancer and metastasis 3, 12, 13 . To identify new potential mediators and drivers of metastatic cancer-induced cachexia, we analyzed five independent metastatic models of colon, breast and lung cancer that gradually develop cachexia during metastatic progression. These analyses identified a zinc transporter, solute carrier family 39, member 14 (Slc39a14, also known as Zip14) 14 , that was significantly upregulated in the cachectic muscles from metastatic cancer mouse models and patients.
Zinc is essential for normal growth and immune function as well as the activity of many transcription factors and enzymes 15, 16 . Interestingly, excess zinc accumulation has been observed in cachectic muscles in animal models and in patients 17, 18 , but the mechanism driving this accumulation and the consequence of muscle zinc overload during cancer metastasis has not been studied. By manipulating Zip14 expression in vivo using mouse models of metastatic cancer, we demonstrate that ZIP14-mediated zinc influx in muscle cells is critical for the development of cancer-induced cachexia. Our findings uncover a new role for ZIP14 in promoting muscle atrophy and potentially blocking muscle regeneration in metastatic cancer.
Results

Development of cachexia in models of metastatic cancer.
To investigate the mechanisms that drive muscle wasting during the advanced stages of cancer 7, 12 , we performed allografts using 4T1 cells, a mouse metastatic breast cancer cell line, and C26m2 cells, a metastatic subline of C26 mouse colon cancer cells that we generated ( Fig. 1a and Supplementary Fig. 1a ,b) through in vivo . To test whether C26m2 and 4T1 cells induce cachexia during metastatic progression, we used a modified tumor-resectionand-relapse approach 20 for metastasis development ( Supplementary  Fig. 1c ). To this end, we engineered each cell line to express luciferase and then subcutaneously implanted them in mice. Resulting tumors were resected 2-3 weeks later, after which bioluminescence imaging confirmed no detectable signal at the implanted site ( Supplementary Fig. 1d ). At 2-3 weeks following tumor resection, we detected distant metastases in C26m2-and 4T1-implanted mice ( Supplementary Fig. 1d ) as well as a concomitant reduction in body weight and grip strength (Fig. 1a,b) . Morphometric analysis of tibialis anterior muscle sections revealed that fiber diameters were markedly reduced compared to control muscles from non-tumor-bearing mice (Fig. 1c,d and Supplementary Fig. 1e ). Importantly, marker genes for muscle atrophy (Trim63 (MuRF1), Fbxo32 (MAFbx, Atrogin1), Fbxo31 and Fbxo30 (MUSA1)) that encode ubiquitin ligases 10, 11 were transcriptionally upregulated in the cachectic tibialis anterior and diaphragm muscles from the 4T1 and C26m2 metastasis models (Fig. 1e) . The following muscle groups also showed induction of the muscle atrophy-related genes: (i) extensor digitorum longus (EDL) muscles with a predominance of fasttwitch, glycolytic fibers, (ii) soleus muscles with a predominance of slow-twitch, oxidative fibers, (iii) gastrocnemius and quadriceps with mixed-fiber types and (iv) cardiac muscles ( Supplementary  Fig. 1f,g ). Notably, cachectic symptoms were not due to anorexia in either model ( Supplementary Fig. 1h ,i). These results indicate that, similar to human cancers 12, 21, 22 , metastatic C26m2 and 4T1 cancer cells systemically induce cachexia in muscle groups comprising diverse fiber types. Furthermore, these metastatic models eliminate the physical complications of a large primary tumor burden 12, 23 and create a protracted therapeutic window for testing potential anticachexia treatments in the context of metastatic disease.
ZIP14 is upregulated in the cachectic muscles from metastatic models. To identify potential mechanisms mediating the development of cachexia in the C26m2 and 4T1 metastatic mouse models, we analyzed the transcriptome of their cachectic tibialis anterior muscles using RNA-seq (Fig. 2a) . Unsupervised principal component analysis showed that the gene expression profiles from cachectic muscles independently segregated from their respective controls ( Supplementary Fig. 2a ). Notably, we observed concordant transcriptional changes in the C26m2 and 4T1 models, which shared 3,140 differentially expressed genes, indicative of overlapping mechanisms ( Supplementary Fig. 2b ). Functional annotation clustering of the common genes (Supplementary Table 1) using Database for Annotation, Visualization and Integrated Discovery (DAVID) identified five clusters with upregulated genes (Fig. 2a and Supplementary Table 2a ) and four clusters with downregulated genes (Supplementary Table 2b ) with enrichment scores (ES) ≥5.0 (P < 0.05). Consistent with previous studies 24, 25 , a marked enrichment in pathways associated with protein degradation (autophagy and proteasome) was observed in cachectic muscles by the following three independent analyses: (i) functional annotation clustering using DAVID (Fig. 2a and Supplementary Table 2a) , (ii) Gene Set Enrichment Analysis (GSEA) using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway gene sets ( Supplementary Fig. 2c ) and (iii) qRT-PCR for genes associated with ubiquitination, ubiquitin-proteasome and autophagy-lysosomal systems ( Supplementary  Fig. 2d,e) . Unexpectedly, genes associated with zinc binding and zinc transport were significantly enriched in the cachectic muscles from the 4T1 and C26m2 metastasis models (ES = 12.08, P < 0.00001; Fig. 2a and Supplementary Table 2a ). In particular, the zinc transporter-encoding gene Zip14 was highly upregulated in the cachectic tibialis anterior and diaphragm muscles and was uniquely upregulated among multiple zinc transporter-encoding genes ( Fig. 2b-d, Supplementary Fig. 2f ,g and Supplementary Table 1) .
Zip14 upregulation was also observed in the cachectic gastrocnemius, quadriceps, soleus, EDL and cardiac muscles ( Supplementary  Fig. 2h ), indicative of Zip14 upregulation in multiple muscle groups during cachexia development.
ZIP14 expression is associated with cachexia development in metastatic cancer and can be upregulated by the TGF-β and TNF-α cytokines. To explore whether Zip14 upregulation is a common phenomenon during metastasis-induced cachexia, we analyzed genetically engineered mouse models (GEMMs), xenograft models and allograft models of metastatic lung cancer 26 ( Fig. 3a and Supplementary Fig. 3a) . GEMMs of metastatic lung cancer driven by conditional expression of Kras G12D combined with either Trp53 (p53) or Stk11 (Lkb1) deletion 26 and a xenograft model of EGFRmutant PC9-BrM3 human lung cancer 27 showed body weight loss and signs of muscle atrophy (Fig. 3a,b) . Notably, Zip14 expression was also induced in the cachectic muscles of these metastatic models (Fig. 3b) . In contrast, upon conditional deletion of Pten and Lkb1 in a lung cancer GEMM 28 , which developed substantial primary tumor burden but no detectable metastases, there was neither marked weight loss nor changes in the expression of muscle atrophy markers or Zip14 at this time point ( Supplementary Fig. 3a-c) . To test whether Zip14 expression can be induced by metastasis in the absence of cachexia, we analyzed an allograft mouse model of metastatic small-cell lung cancer (SCLC) driven by conditional deletion of Rb1 (Rb) and p53 that fails to induce cancer-associated muscle wasting ( Fig. 3b and Supplementary Fig. 3a ,d,e). Our results (Figs. 2d and 3a,b) indicate that upregulation of Zip14 in muscle is specifically associated with cachexia in diverse metastatic models across several cancer types.
To next evaluate the clinical relevance of Zip14 upregulation in human cancer cachexia, we performed immunohistochemical analyses on muscle sections from patients with advanced cancer and metastatic disease. Blinded pathological examination revealed that samples from 19 of 43 patients with cancer cachexia showed specific ZIP14 staining in atrophic muscle fibers compared to 8 of 53 patients with noncachectic cancer (Pearson's chi-square test, P = 0.002; Fig. 3c, Supplementary Fig. 3f -h and Supplementary Table 3) . Importantly, ZIP14 staining was low in the nonatrophic fibers in muscles from both patient groups (Fig. 3c) . Staining with two additional anti-ZIP14 antibodies validated these findings ( Supplementary Fig. 3i ). Thus, ZIP14 protein levels are significantly elevated in the atrophic muscle fibers of patients with advanced cancer.
To identify soluble factors that can upregulate Zip14 during cachexia, we analyzed signaling pathways in cachectic muscles using Ingenuity pathway analysis (IPA). We queried the list of differentially expressed genes (Supplementary Table 1 ) in cachectic muscles shared between the 4T1 and C26m2 metastasis models for upstream transcriptional regulators ( Supplementary  Fig. 3j and Supplementary Tables 4 and 5 ). We tested candidate pathways and found that treatment of human primary muscle cells and murine C2C12 myoblasts with recombinant tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β proteins significantly induced Zip14 expression ( Fig. 3d and Supplementary Fig. 3k ). Importantly, Zip14 expression was blocked in both human primary muscle cells and mouse C2C12 cells through inhibition of TNF-α -induced activation of nuclear factor (NF)-κ B with BAY 11-7085 and through inhibition of TGF-β -induced SMAD phosphorylation with the TGF-β RI kinase inhibitor SB431542 (but not through inhibition of TNF-α -induced activator protein 1 (AP-1) transcription factor c-Jun (c-Jun/AP1) activation with CC-401) ( Fig. 3d and Supplementary  Fig. 3k-m) . TNF-α and TGF-β cytokines are intricately linked to cancer metastasis 29, 30 and were detected in the C26m2 and 4T1 metastatic tumor microenvironments ( Supplementary Fig. 3n,o) . . Mouse images were taken at endpoint at 6 weeks after 4T1 injection and 7 weeks after C26m2 injection. n = 6 Con mice and n = 9 Tb mice (4T1); n = 10 Con mice and n = 9 Tb mice (C26m2). b, Measurements of hind-limb grip strength of mice bearing 4T1 or C26m2 metastases at 5 weeks following tumor-cell injection. n = 5 mice per group. Values were normalized to control. c,d, Representative immunofluorescence images (c) and associated morphometric analysis (d) of cross-sections from tibialis anterior (TA) muscles from mice at 5 weeks following tumor-cell injection, compared to their respective non-tumor-bearing controls. Muscle sections in c were immunostained with antibody against laminin (shown in red, staining muscle cell membranes) and stained with DAPI (shown in blue, staining cell nuclei). Scale bars, 50 µ m.
Results from morphometric analysis are depicted in d as the distribution frequency of fiber size categorized by fiber diameter. n = 3 mice per group (4T1); n = 4 Con mice and n = 3 Tb mice (C26m2). e, Results from qRT-PCR analysis of muscle atrophy markers Trim63, Fbxo32 (MAFbx), Fbxo31 and MUSA1 in TA and diaphragm muscles. For TA muscles (4T1): n = 4 Con mice and n = 7 Tb mice for Trim63 expression; n = 4 Con mice and n = 6 Tb mice for MAFbx expression; n = 6 Con mice and n = 7 Tb mice for Fbxo31 and MUSA1 expression. For TA muscles (C26m2): n = 5 Con mice and n = 3 Tb mice for Trim63 and MAFbx expression; n = 5 Con mice and n = 5 Tb mice for Fbxo31 and MUSA1 expression. For diaphragm muscles (4T1 and C26m2): n = 6 mice per group. All data are shown as mean ± s.e.m. P values were determined by the two-tailed, unpaired Student's t-test (a,b,e) and two-sided Welch's t-test (d).
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Moreover, elevated levels of TNF-α and TGF-β cytokines have been reported in the serum of mouse models and of patients with advanced cancers, and they are known to activate many cachexiapromoting signaling pathways 3, 29, 31, 32 . Importantly, neutralization of TGF-β and TNF-α using a pan-TGF-β -neutralizing antibody (clone 1D11) or TNF-α neutralizing antibody (clone XT3.11) reduced Zip14 expression in the tibialis anterior muscles in 4T1 and C26m2 metastasis models (Fig. 3e,f) and was associated with a concomitant reduction in SMAD2 phosphorylation and NF-κ β activation ( Supplementary Fig. 3p,q) . These findings suggest that TGF-β and TNF-α cytokines contribute to ZIP14 upregulation in cachectic muscles from metastatic cancer models.
ZIP14 upregulation and zinc accumulation in muscle mediates cancer-induced cachexia. To determine whether ZIP14 is required for the development of cancer-induced cachexia, we implanted cancer cells subcutaneously into mice with germline knockout of Zip14 and mice with wild-type Zip14 and evaluated the effects of ZIP14 loss (Fig. 4a-c and Supplementary Fig. 4a ). Zip14-knockout mice are viable but display dwarfism, scoliosis, shortened bones, defective cartilage formation and behavioral problems 14, 33 . Upon tumor implantation, Zip14-knockout and wild-type mice developed metastases with similar tumor burden ( Supplementary Fig. 4b ). Notably, Zip14-deficient mice were significantly resistant to cancerinduced muscle wasting (Fig. 4a-c and Supplementary Fig. 4c,d ). 
Fig. 2 | The metal-ion transporter gene
Zip14 is upregulated in cachectic muscles from both 4T1 and C26m2 metastatic mouse models. a, Transcriptomic profiling by RNA-seq analysis of TA muscles collected from mice with 4T1 or C26m2 metastases (Tb) or non-tumor-bearing, age-matched controls (Con) at 5 weeks following tumor-cell injection (see Fig. 1a ). For the full lists of shared differentially expressed genes and functionally annotated clusters, see Supplementary Tables 1 and 2 , respectively. Significant functional clusters of upregulated genes with an enrichment score (ES) > 5.0 and a P value < 0.05 are shown in a. n = 2 Con mice and n = 2 Tb mice (4T1) and n = 2 Con mice and n = 2 Tb mice (C26m2) were used for transcriptomic profiling and subsequent analysis. b, Top 10 upregulated genes in cachectic muscles from 4T1 and C26m2 metastasis models (from analysis in a) sorted by decreasing log 2 fold change (in C26m2 data) with a q value cutoff of 0.05 are shown as an alphabetically ordered heat map. FPKM, fragments per kilobase of transcript per million mapped reads. c, Expression levels of the Slc39 family of zinc influx transporter genes in cachectic muscles profiled in RNA-seq analysis (in a) are shown relative to their respective controls. Slc39a14 (also known as Zip14) is highlighted in red on the heat maps in b and c. d, Results from qRT-PCR analysis of Zip14 in TA muscles and diaphragm muscles from 4T1-or C26m2-tumor-bearing mice and from respective controls. For TA muscles: n = 9 Con mice and n = 14 Tb mice (4T1); n = 8 Con mice and n = 8 Tb mice (C26m2). For diaphragm muscles: n = 5 Con mice and n = 7 Tb mice (4T1); n = 6 Con mice and n = 5 Tb mice (C26m2). All data are shown as mean ± s.e.m. P values were determined by the one-tailed Fisher's exact test (a), which were further corrected using the Benjamini-Hochberg procedure, or by the two-tailed, unpaired Student's t-test (d).
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Examination of gastrocnemius, tibialis anterior and EDL muscles revealed no change in the distribution of oxidative and glycolytic fibers, fiber-type switching or vascularization between wild-type and Zip14-knockout mice in the presence or absence of tumor burden, as determined by succinate dehydrogenase (SDH) staining, immunostaining analysis using antibodies against myosin heavy chain (MyHC) isoforms and quantitation of CD31 + capillaries per fiber by immunostaining analysis, respectively ( Supplementary  Fig. 4e-h and data not shown) . These results suggest that ZIP14 mediates cancer-induced muscle wasting.
To rule out secondary effects of germline Zip14 loss, we depleted Zip14 levels in muscles using shRNA-mediated knockdown and determined its effect on cancer-induced cachexia. To this end, we transduced gastrocnemius muscles with an adeno-associated virus (AAV) expressing mCherry (to confirm successful transduction) in combination with either a shRNA targeting Zip14 (shZip14) or a scrambled control (shCon; Fig. 4d ). We injected a group of these mice with C26m2 cancer cells and monitored metastasis and cachexia development (as shown in Fig. 1a and Supplementary Fig. 1c) , and remaining mice were used as non-tumor-bearing controls. We confirmed Zip14 knockdown in muscles through both qRT-PCR and immunostaining analysis ( Fig. 4d and Supplementary Fig. 4i , respectively). Consistent with the findings in Zip14-knockout mice ( Fig. 4a-c) , Zip14 knockdown in muscles was also associated with a significant rescue of cancer-induced muscle atrophy ( Fig. 4e-g and Supplementary Fig. 4j ). No differences in tumor burden ( Supplementary Fig. 4k ), distribution of oxidative and glycolytic fibers, fiber type and vascularization were observed between the shCon and shZip14 groups ( Supplementary Fig. 4l-n) . In contrast, Zip14 depletion in the muscles of normal mice had no prominent phenotype without any tumor burden (Supplementary Fig. 4o-s) . These findings support the notion that muscle-specific Zip14 expression is required for muscle wasting in the context of metastatic cancer.
Considering the induction of genes encoding zinc-binding proteins in cachectic muscles (Fig. 2a,b ) and the ability of ZIP14 to transport zinc in other tissues 14, 34 , we asked whether ZIP14 imports zinc into muscle cells. Indeed, mice harboring C26m2 and 4T1 metastases showed aberrant accumulation of zinc in the cachectic muscles (gastrocnemius, tibialis anterior, diaphragm, quadriceps, soleus, EDL and cardiac) with a concomitant reduction in the serum zinc levels ( Fig. 4h and Supplementary Fig. 4t ), as determined by inductively coupled-plasma mass spectrometry (ICP-MS). Consistent with these findings, higher intracellular zinc levels were detected in single myofibers isolated from cachectic mice, as analyzed by laser-ablation ICP-MS (LA-ICP-MS) ( Supplementary  Fig. 4u ). In contrast, tumor-bearing Zip14-null mice showed no additional zinc accumulation in muscles compared to non-tumorbearing Zip14-null mice (Supplementary Fig. 4v ). To determine whether overexpression of ZIP14 can augment zinc uptake in muscle cells, we expressed either GFP (control) or Zip14 in C2C12 myoblasts ( Supplementary Fig. 4w ). We next added zinc to the culture medium and measured zinc uptake using a FluoZin-3 fluorescencebased assay. Irrespective of differentiation status, Zip14-expressing C2C12 cells showed a marked increase in zinc uptake, as measured by reduction of zinc levels in the culture medium ( Supplementary  Fig. 4w ). These results demonstrate that ZIP14 likely functions as a zinc transporter in muscle cells.
We next reasoned that if ZIP14-mediated zinc uptake promotes the development of cancer-induced cachexia, then excess zinc should exacerbate muscle wasting in the context of cancer. In the absence of tumors, zinc supplementation had no detrimental effect on the growth kinetics of wild-type Zip14 and Zip14-knockout mice (Fig. 4i) . Strikingly, excess zinc induced a substantial acceleration in body weight loss and an increase in muscle atrophy in wild-type Zip14, but not Zip14-knockout, tumor-bearing mice (Fig. 4i,j) . No changes in food and water intake, behavior and function of liver and kidney were observed in tumor-bearing mice with excess zinc supplementation, thereby ruling out acute toxicity effects ( Supplementary Fig. 4x ). The Zip14-and zinc-mediated cachexia was also not secondary to altered tumor burden because tumor volume was comparable between wild-type Zip14 and Zip14-knockout mice ( Supplementary Fig. 4y ). These results indicate that excess zinc promotes muscle wasting in mice specifically in the presence of Zip14 and cachexia-inducing metastatic tumors.
ZIP14-mediated zinc uptake blocks muscle-cell differentiation and induces myosin heavy chain loss. To understand how ), both from which muscles were collected at 13 weeks following adeno-Cre induction; PC9-BrM3 xenograft, from which muscles were collected at 7 weeks following tumorcell injection; and Rb/p53-deleted allograft, from which muscles were collected at 6 weeks following tumor resection (see also Supplementary Fig. 3a ).
Results were compared to those from respective controls. For body weight analysis in a: n = 4 Con mice and n = 8 Tb mice (Kras/p53); n = 3 Con mice and n = 6 Tb mice (Kras/Lkb1); n = 3 Con mice and n = 10 Tb mice (PC9-BrM3 xenograft); n = 3 Con mice and n = 10 Tb mice (Rb/p53-mutated allograft). For qRT-PCR analysis in b: n = 6 Con mice and n = 4 Tb mice (Kras/p53); n = 3 Con mice and n = 4 Tb mice (Kras/Lkb1); n = 4 Con mice and n = 5 Tb mice (PC9-BrM3 xenograft); n = 5 Con mice and n = 4 Tb mice (Rb/p53-mutated allograft). c, Representative images of ZIP14 immunohistochemistry on human muscle cross-sections from patients with noncachectic (top) or cachectic (bottom) metastatic cancer. n = 3 patients per group shown. ZIP14 antibody details are provided in Supplementary Fig. 3f -h, and patient details are listed in Supplementary Table 3 . Scale bars, 50 µ m. ca, cancer. Data is representative of three independent experiments. d, qRT-PCR analysis of Zip14 in human skeletal primary muscle cells treated with vehicle, TNF-α (50 ng/ml), TGF-β (10 ng/ml) or both TNF-α (50 ng/ml) and TGF-β (10 ng/ml) either alone (vehicle) or in the presence of 10 µ M of the indicated inhibitors. Cells were pretreated with either vehicle or the indicated inhibitors for 1 h before addition of the cytokines (TGF-β for 9 h and TNF-α for 3 h before harvest). Cells from all groups were harvested at the same time. n = 6 samples for cells treated with vehicle, TGF-β alone or both TNF-α and TGF-β ; n = 4 samples for all the other groups. Inhibitors: NF-κ Bi, NF-κ B inhibitor (BAY 11-7085); AP1i, AP1 inhibitor (CC401); SMADi, TGF-β receptor type I inhibitor (SB431542). e,f, Results from qRT-PCR analysis of Zip14 in TA muscles after neutralizing antibody treatment in mice injected with either 4T1 (e) or C26m2 (f) tumor cells. Mice were treated with an isotype control antibody, a neutralizing antibody against TNF-α or TGF-β or with both neutralizing antibodies (200 µ g antibody per mouse, treated three times per week) starting 1 week after surgery, for a period of 1 week. For the 4T1 model: n = 8 non-Tb Con mice; n = 5 Tb mice treated with isotype control; n = 6 Tb mice treated with TNF-α antibody; n = 7 Tb mice treated with TGF-β antibody; n = 3 Tb mice treated with both TNF-α and TGF-β antibodies. For the C26m2 model: n = 5 non-Tb con mice; n = 6 Tb mice treated with isotype control; n = 4 Tb mice treated with TNF-α antibody; n = 3 Tb mice treated with TGF-β antibody; n = 5 Tb mice treated with both TNF-α and TGF-β antibodies. All data are shown as mean ± s.e.m. P values were determined by the two-tailed, unpaired Student's t-test in (a,b) or by a one-way ANOVA with post hoc Tukey's test (d-f) with F value (DFn, DFb): d, F(9, 36) = 161.9; e, F(4, 24) = 10.3; and f, F(4, 18) = 20.7. n.s., not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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NaTuRe MedICINe excess zinc might perturb muscle homeostasis and mediate muscle atrophy, we first examined which cell types in cachectic muscles express ZIP14. To this end, we purified progenitor subpopulations in muscles 35 through magnetic and flow cytometry-assisted sorting ( Fig. 5a and Supplementary Fig. 5a ). In muscles from both C26m2 and 4T1 metastasis models, Zip14 was specifically induced in CD31 -CD34
+ cells ( Fig. 5a ), which comprise the muscle satellite-cell population associated with cachexia 35 , and we confirmed this finding in human muscle satellite cells expressing paired box 7 (PAX7) ( Supplementary Fig. 5b ). We also observed ZIP14 expression in mature, differentiated myofibers from cachectic muscles in the C26m2 metastasis model (Fig. 5b) . Therefore, ZIP14-mediated zinc accumulation may negatively impact both the process of muscle-cell differentiation and the function of differentiated muscle fibers.
Normal muscles respond to muscle injury by activation and proliferation of muscle satellite cells into myoblasts that differentiate to regenerate new muscle fibers 36 ( Supplementary Fig. 5c ). In contrast, in cancer-induced muscle atrophy, muscle damage is followed by proliferation of muscle progenitor cells that eventually fail to differentiate 35, 37 ( Supplementary Fig. 5c ). We first tested whether aberrant Zip14 upregulation and consequent zinc influx in muscle progenitor cells affect normal differentiation using C2C12 myoblasts and primary myoblasts ( Fig. 5f ). In contrast, in the presence of zinc, the differentiation of Zip14-expressing myoblasts was selectively blocked ( Fig. 5g ,h). These findings suggest that ZIP14-mediated zinc uptake in muscle progenitor cells interferes with muscle-cell differentiation. Muscle-cell differentiation is tightly regulated by the MyoD and MEF2 family of transcription factors 36, 38 . We therefore considered the possibility that excess zinc could repress the levels or activity of myogenic transcription factors to block muscle-cell differentiation. Indeed, treatment of Zip14-expressing C2C12 myoblasts with zinc led to transcriptional repression of MyoD, Mef2c and Myf5 (Fig.  5e ) but not Ccnd1 (Cyclin D1) ( Supplementary Fig. 5i ), which controls proliferation and cell-cycle exit of myoblasts 39, 40 . Furthermore, GSEA using the HALLMARK_MYOGENESIS gene set querying the cachexia signature derived from C26m2 and 4T1 metastasis models (Supplementary Fig. 5j and Supplementary Table 1) was supportive of repressed myogenesis in cachectic muscles 32 . Consistently, MyoD and Mef2c expression was downregulated ( Fig. 5f ) in cachectic muscles from C26m2 and 4T1 metastasis models as compared to non-tumor-bearing controls (Supplementary Table 1 ). These findings identified a potential link between ZIP14-induced zinc accumulation in muscle progenitor cells and impaired muscle regeneration in the context of metastatic cancer.
Finally, we questioned whether ZIP14-mediated zinc accumulation in the mature muscle fibers (Fig. 5b ) of cachectic muscles mediates cancer-induced muscle atrophy. Myofibrils constitute the organizational units in muscle with aligned thick and thin filaments that facilitate muscle contraction 10 . Myofibrillar proteins comprise over 70% of muscle proteins, and their reduced synthesis or loss negatively affects fiber size and function 6, 41 . We therefore asked whether ZIP14-mediated zinc influx affects myofibrillar protein levels. To this end, we first differentiated Zip14-expressing and control myoblasts into myotubes. Myotubes were then treated with zinc for 24 h, and myofibrillar proteins were extracted using a high-salt lysis method 42 . A striking loss in MyHC protein was observed by immunoblot analysis in Zip14-expressing myotubes treated with zinc ( Fig. 5g) , which was confirmed by immunofluorescence analysis ( Supplementary Fig. 5k,l) . In contrast, no major reduction in the thin filament proteins skeletal actin, tropomyosin and troponin, the intermediate filament protein desmin and the thick filament protein myosin light chain (MyLC) were detected under these conditions ( Fig. 5g and Supplementary Figs. 5k-m and 6). Furthermore, fractionation of muscle proteins showed that both the soluble and myofibrillar fractions of MyHC decreased in Zip14-expressing myotubes with zinc treatment relative to the other myofibrillar proteins and associated morphometric analysis (b) of cross-sections of gastrocnemius muscles harvested from wild-type Zip14 (WT) and Zip14-knockout (KO) mice at 5 weeks post 4T1-cell injection and from controls. Sections in a were immunostained with antibody against laminin (shown in green, staining muscle cell membranes) and stained with DAPI (shown in blue, staining cell nuclei). Scale bars, 50 μ m. Morphometric analysis in b is depicted as the distribution frequency of fiber size categorized by fiber diameter. n = 4 Con-WT mice and n = 3 mice for all other groups. c, Results from qRT-PCR analysis of the indicated atrophy markers in gastrocnemius, TA or diaphragm muscles from wild-type Zip14-and Zip14-knockout mice, with or without 4T1 tumorcell injection, collected 5 weeks following injection. For gastrocnemius muscles: n = 7 Con-WT mice, n = 5 Tb-WT mice (4T1), n = 6 Con-KO mice and n = 7 Tb-KO mice (4T1) for Trim63 expression; n = 7 Con-WT mice, n = 6 Tb-WT mice (4T1), n = 6 Con-KO mice and n = 8 Tb-KO mice (4T1) for MAFbx expression; n = 7 Con-WT mice, n = 5 Tb-WT mice (4T1), n = 6 Con-KO mice and n = 9 Tb-KO mice (4T1) for Fbxo31 expression; n = 7 Con-WT mice, n = 7 Tb-WT mice (4T1), n = 6 Con-KO mice and n = 10 Tb-KO mice (4T1) for MUSA1 expression. For TA muscles: n = 7 Con-WT mice, n = 6 Tb-WT mice (4T1), n = 5 Con-KO mice and n = 7 Tb-KO mice (4T1) for Trim63 and MAFbx expression; n = 5 Con-WT mice, n = 5 Tb-WT mice (4T1), n = 5 Con-KO mice and n = 8 Tb-KO mice (4T1) for Fbxo31 expression; n = 5 Con-WT mice, n = 6 Tb-WT mice (4T1), n = 5 Con-KO mice and n = 8 Tb-KO mice (4T1) for MUSA1 expression. For diaphragm muscles: n = 3 mice per group. Data were normalized to those collected from non-Tb wild-type Zip14 mice. d, AAV vectors expressing mCherry and an shRNA targeting either a control scrambled sequence (shCon) or Zip14 (shZip14) were injected intramuscularly into the gastrocnemius muscles and were monitored by fluorescence imaging. A representative image taken 5 weeks after injection of AAV particles is shown (top). C26m2 cancer cells were then subcutaneously injected, and muscles were collected 5 weeks following tumor-cell injection. Zip14 expression was then determined by qRT-PCR analysis (bottom). n = 4 mice per group. Data were normalized to those collected from shCon-injected mice. e,f, Representative immunofluorescence staining images of laminin (e) and morphometric analysis of muscle size (f) in gastrocnemius muscles from C26m2 tumor-bearing (Tb) mice injected with either shCon or shZip14. Sections in e were immunostained with antibody against laminin (shown in green, staining muscle cell membranes) and stained with DAPI (shown in blue, staining cell nuclei). Scale bars, 50 μ m. Results from morphometric analysis are depicted in f as the distribution frequency of fiber size categorized by fiber diameter. n = 3 mice for shCon and n = 4 mice for shZip14. g, Results from qRT-PCR analysis of the indicated genes in gastrocnemius muscles from the C26m2 Tb mice shown in d. n = 4 mice per group. Data were normalized to those collected from shCon-injected mice. h, Zinc levels in gastrocnemius (Gast), TA and diaphragm (Dia) muscles (µ g/g of dry weight) determined by ICP-MS analysis in either non-tumor-bearing control mice or mice bearing either 4T1 or C26m2 metastases collected at 5 weeks following tumor-cell injection. For the 4T1 model: n = 7 Con mice and n = 8 Tb mice for gastrocnemius muscles; n = 4 Con mice and n = 6 Tb mice for TA muscles; n = 3 mice per group for diaphragm muscles. For the C26m2 model: n = 7 mice per group for gastrocnemius muscles; n = 3 mice per group for TA muscles; n = 8 Con mice and n = 10 Tb mice for diaphragm muscles. i,j, Body weight analysis (i) and qRT-PCR analysis of the indicated genes in TA muscles (j) of wild-type Zip14 and Zip14-knockout mice that were injected with C26m2 cancer cells and of respective non-tumor-bearing control mice. Mice were subdivided into two groups on the day of tumor-cell injection and were treated with either normal or zinc-supplemented drinking water (Zn) for the indicated number of days in i. TA muscles were collected for qRT-PCR analysis in j after 15 d on zinc-supplemented water. For body weight analysis in i: n = 8 mice for Con-WT, Tb-WT and Tb-WT + Zn; n = 7 mice for WT + Zn; n = 4 mice for Con-KO, Con-KO + Zn and Tb-KO; and n = 5 mice for Tb-KO + Zn. For gene expression analysis in j: n = 5 mice for Con-WT; n = 3 mice for Con-WT + Zn, Tb-WT, Con-KO, Con-KO + Zn and Tb-KO; n = 7 mice for Tb-WT + Zn; n = 4 mice for Tb-KO + Zn for analyzing Trim63 and MAFbx; n = 5 mice for Con-WT, n = 3 mice for Con-WT + Zn, Tb-WT and Con-KO + Zn; n = 7 mice for Tb-WT + Zn; n = 4 mice for Con-KO, Tb-KO and Tb-KO + Zn mice for analyzing Fbxo31 and MUSA1. Data in j were normalized to those collected from non-tumor-bearing wild-type Zip14 mice on regular water without zinc supplementation. All data are shown as mean ± s.e.m. P values were determined by the two-tailed, Fig. 5n ). These results suggest that ZIP14-mediated zinc accumulation induces the loss of both soluble and sarcomeric MyHC in mature muscle cells.
The ubiquitin-proteasome system (UPS) is one of the central pathways that regulates MyHC turnover in muscle atrophy sta tes 10, 41, 43, 44 , and loss of MyHC is associated with loss of muscle mass and function during cancer cachexia 45 . Therefore, we asked whether ubiquitin-mediated proteasomal degradation promotes MyHC loss in the context of ZIP14-mediated zinc influx and cancer-induced muscle wasting. Indeed, MyHC loss in differentiated C2C12 cells was associated with upregulation of the UPS pathway-related genes Trim63, Psma1, Psmc4, Psmd11 and Ubc ( Supplementary  Fig. 5o ) and could be blocked by the proteasome inhibitor MG132 (Supplementary Fig. 5p ). Consistent with results from our in vitro studies, MyHC levels in cachectic muscles from the metastasis models were restored to normal in response to either Zip14 knockdown (C26m2 model; Fig. 5h ) or loss (4T1 model; Fig. 5i) , with no reduction in the expression of the other myofibrillar proteins examined ( Supplementary Fig. 5q ). To confirm the specificity of MyHC regulation in vivo by Zip14, we re-expressed Zip14 in Zip14-deficient muscles. To this end, we transduced the gastrocnemius muscles of mice with germline knockout of Zip14 with Zip14-expressing AAV or mCherry-expressing AAV as a control (Supplementary Fig. 5r ). We implanted 4T1 cancer cells subcutaneously and evaluated the effects of Zip14 re-expression in muscle during cancer-induced cachexia. Importantly, expression of Zip14 in muscles reestablished 
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+ cells were purified from gastrocnemius muscles using a combination of magnetic and flow-cytometry-assisted sorting (see Supplementary Fig. 5a ). For the 4T1 model: n = 4 Con mice for isolated CD34 Fig. 2 and Supplementary Table 1) comparing TA muscles from non-tumor-bearing control mice to mice bearing 4T1 or C26m2 metastases that were collected 5 weeks following tumor-cell injection. g, MyHC and tropomyosin (Tm) protein expression as determined by immunoblot analysis in C2C12 cells infected with adenovirus expressing either control or Zip14 cDNA and differentiated for 3 d followed by treatment with either 0 or 50 μ M ZnCl 2 for 24 h. Data are representative of three independent experiments. h, Immunoblot analysis probing for MyHC and Tm in gastrocnemius muscles from mice intramuscularly injected with AAV expressing either shCon or shZip14 and subsequently injected with C26m2 cancer cells (see Fig. 4d ). Age-matched, non-tumor-bearing mice were used as a control. Data is representative of three independent experiments. i, Immunoblot analysis probing for MyHC and Tm in gastrocnemius muscles from the indicated groups. Muscles were isolated from wild-type Zip14 and Zip14-knockout mice with or without 4T1 metastases. Another cohort of Zip14-knockout mice were injected intramuscularly with AAV-Con (mCherry) or AAV-Zip14 in the gastrocnemius muscle and then were injected 4 weeks later with 4T1 tumor cells. All muscles were collected 5 weeks following tumor-cell injection. Data are representative of three independent experiments. All data are shown as mean ± s.e.m. All P values were determined by the two-tailed, unpaired Student's t-test. Uncropped immunoblot images are shown in Supplementary Fig. 6 . j, A schematic of the working model. During cancer progression and metastasis development, cytokines such as TNF-α and TGF-β upregulate the expression of Zip14, a metal-ion transporter, in muscle progenitor and mature muscle cells. This causes an aberrant accumulation of zinc in these muscle cells. ZIP14 expression and zinc uptake in muscle progenitor cells represses MyoD and Mef2c expression and blocks muscle-cell differentiation. ZIP14 expression in mature muscle cells causes MyHC loss, which promotes cancer-induced muscle atrophy in metastatic cancers. Tf, tumor factors; Ca, cancer cells; Nr, normal cells.
the muscle atrophy phenotype in tumor-bearing Zip14-deficient mice ( Supplementary Fig. 5s-u) , resulting in substantial MyHC loss (Fig. 5i) . No changes in the other myofibrillar proteins, fiber type and vascularization were observed ( Fig. 5i and Supplementary  Fig. 5v-w) . In addition, MyHC levels did not change with Zip14 expression in the muscles from non-tumor-bearing mice, which underlines the importance of the tumor context in Zip14 function ( Supplementary Fig. 5x,y) . These results suggest that Zip14 mediates muscle atrophy through MyHC loss in metastatic cancer.
Discussion
Our understanding of cancer has expanded from a focus on strictly cell-autonomous processes to a complex interplay involving cellextrinsic, reciprocal interactions with the tumor microenvironment 1 . It is now clear that cancer evolves as a systemic disease in which the influence of the tumor extends far beyond the site of tumor growth and invasion to distant tissues 4, 5 . We demonstrate that zinc accumulates in skeletal muscles, far from the actual site of tumor growth, through aberrant upregulation of the ZIP14 metalion transporter, and this phenomenon is a critical mediator of metastatic cancer-induced muscle wasting (Fig. 5j) . Our studies could provide a basis for the design of anti-cachexia therapies that target ZIP14 in patients with metastatic cancers.
Zinc homeostasis is perturbed in many advanced human cancers. For instance, serum zinc levels were significantly reduced in patients with metastatic cancer 46 , but whether this correlated with an increase in zinc uptake by other tissues was not explored. In a pilot clinical study, muscle zinc levels nearly doubled in patients with cachectic cancer with > 9.5% body weight loss 18 , although these clinical observations were not further investigated. Excess zinc accumulation in muscles has also been previously reported in animal models of cancer-induced cachexia 17, 18, 47 . Interestingly, redistribution of zinc has been reported in response to administration of IL-1α , glucagon and epinephrine, and 6 h following IL-1α administration in mice, a transient reduction (of up to 25%) in plasma zinc levels correlated with a dramatic increase in zinc uptake in liver, bone marrow and thymus 48 . However, the kinetics of zinc tissue redistribution in the context of cancer progression have not yet been studied. This information will be key to understanding how the systemic regulation of ZIP14 expression affects cancer-induced muscle atrophy. Aberrant zinc regulation may also be an underlying cause of other muscle-wasting pathologies, such as dexamethasoneinduced muscle atrophy 49 and muscular dystrophy 50 , but whether upregulation of ZIP14 also contributes to the development of these muscle-wasting conditions remains to be further explored. It is well established that metallothioneins (MT), which are cysteine-rich metal-binding proteins, function in cellular zinc homeostasis 16 . Interestingly, metallothionein 1 (Mt1) and Mt2 are upregulated in muscle atrophic conditions, and their loss promotes muscle hypertrophy 49, 51 . Moreover, metallothionein deficiency can protect from glucocorticoid-induced atrophy 49 . In line with these findings, our studies show a robust induction of Mt1 and Mt2 in cachectic muscles from metastasis mouse models (Fig. 2b) , which is supportive of the perturbed zinc homeostasis in these muscles. It will be interesting to further investigate the contribution of metallothioneins and other molecules involved in zinc regulation to the development of metastatic cancer-induced cachexia. Therefore, the ability to manipulate zinc influx into muscle cells has potentially far-reaching implications for a number of muscle diseases.
As we found that ZIP14 is upregulated in cachectic muscles in both mouse models and patients with metastatic cancer across multiple cancer types, it is likely that shared metastasis-associated factors regulate its expression. Previous studies showed that Zip14 expression is induced in liver cells in response to infection, tissue injury, inflammation and chronic diseases by proinflammatory cytokines, such as IL-6 and IL1-β (refs 14, 16, 34 ). Here, we show that TGF-β and TNF-α , two cytokines that are associated with metastatic cancers 3, 29, 52 , are likely inducers of Zip14 expression in muscle. However, as neutralization of TGF-β and/or TNF-α cytokines in metastatic models significantly reduced but did not completely abrogate Zip14 expression, it is possible that additional metastasisassociated factors that are not yet identified contribute to its upregulation in muscles.
Our study suggests that ZIP14 upregulation in muscle cells serves as a driver of metastatic cancer-induced muscle atrophy rather than arising as an indirect consequence of muscle wasting. The key findings that are supportive of this notion are that loss of Zip14 dramatically reduced muscle atrophy in our metastatic cancer models and that Zip14 re-expression restored it. However, it is important to note that in the absence of tumor burden, overexpression of Zip14 in muscle is not sufficient to induce muscle wasting, which implies that zinc and potentially other metastasis-induced cofactors collaborate with ZIP14 to induce cachexia. It is also likely that other minerals, such as calcium, magnesium, manganese and/or iron, impact the process of cachexia development. Interestingly, ZIP14 has been implicated in iron and manganese transport in liver and brain, respectively 14, 16 ; however, this function of ZIP14 has not yet been explored in muscle. In the context of bone metastases, calcium mishandling through the TGF-β -NAPDH oxidase 4 (NOX4)-ryanodine receptor (RyR1) axis has been shown to reduce force generation and promote muscle weakness 3 . These studies suggest that cachexia development is likely regulated by multiple factors in metastatic cancers.
A prominent characteristic of muscle atrophy is a cellular shift toward protein catabolism, which is largely mediated by the activation of the ubiquitin-mediated proteasome and autophagy pathways 10, 41, 53 . Consistent with previous studies 44 , 45, 53 , cachectic muscles from metastatic mouse models showed robust transcriptional upregulation of atrophy-associated genes of the ubiquitin-proteasome and autophagy-lysosome degradation pathways along with a reduction in the myofibrillar protein MyHC. Importantly, MyHC loss in muscles has been observed in patients with cachexia and in animal models 42, 45, 54, 55 , suggesting that this typically abundant myofibrillar protein greatly impacts muscle size and function. In particular, its loss in diaphragm muscles may underlie respiratory failure in patients with cancer 42 . MyHC loss can be triggered in response to several atrophy-inducing factors, such as TNF-α and interferon (IFN)-γ cytokines 45 and the glucocorticoid dexamethasone 44 , and as presented here, with aberrant ZIP14 upregulation and zinc accumulation in muscle. It is interesting to note that in denervation-induced muscle atrophy, the degradation of thick filament proteins, such as myosin binding protein C (MyBP-C), MyLC-1 and MyLC-2, occurs in a tripartite motif-containing 63 (TRIM63)-dependent manner before MyHC loss 43 . In the context of our studies demonstrating the loss of MyHC in zinc-treated Zip14-expressing myotubes in vitro and in metastasis-induced cachectic muscles in vivo, the events that mediate MyHC loss, the order of disassembly of the other myofibrillar components and the specific role of the UPS and/or autophagy components in this regulation remain to be further investigated.
Zinc can serve as an intracellular signaling molecule 56 , and 10% of the encoded proteins in the human genome are predicted to bind zinc through zinc-finger motifs 57 . Moreover, zinc functions as a structural and catalytic component of over 300 enzymes and transcription factors. Interestingly, the E3 ubiquitin ligase TRIM63 is a member of the zinc-finger family of proteins that has been shown to physically bind to MyHC to induce its proteolysis 44 . In our study, Trim63 mRNA levels increased in cachectic muscles in metastatic models and in Zip14-expressing myotubes when exposed to excess zinc. Interestingly, it has been reported that increased activity of E3 ubiquitin ligases during catabolic conditions triggers their autoubiquitination and subsequent degradation and that transcriptional induction of these ligases during atrophy could replenish their levels during enhanced protein breakdown 11 .
Articles
NaTuRe MedICINe
The upregulation of Zip14 in muscle satellite cells in response to tumor factors has therapeutic implications. Healthy muscle responds to injury by stimulating the activation and proliferation of satellite cells, which ultimately fuse to regenerate new muscle 38, 58 . Muscle atrophy in response to tumor burden also triggers membrane damage and activation of the muscle satellite cells 35, 37 ; however, subsequent regeneration of muscle is thought to be impaired 59 . This aberrant response to muscle injury differs from muscular dystrophies in which muscle necrosis and degeneration are dominant features and which eventually results in nonfunctional fatty and fibrous tissue 60 . Whether impaired regeneration represents an indirect consequence or a contributing factor to cancer-induced cachexia remains to be further investigated. However, it is likely that if muscle regeneration can be restored in atrophic muscles with simultaneous inhibition of muscle degradation, the cachexia phenotype could be substantially ameliorated in cancer. As ZIP14 and zinc influx in satellite cells repress muscle differentiation through the downregulation of MyoD and Mef2c, inactivation of ZIP14 may also represent a means to restore normal muscle regeneration in metastatic cancer.
Zinc is indispensable for cellular functions and is tightly regulated at both the systemic and cellular levels 16 . Indeed, we observed normal growth and body weight gain in healthy mice treated with zinc-supplemented water, whereas tumor-bearing mice showed accelerated body weight loss and muscle wasting in a Zip14-dependent manner. Our present findings in animal models therefore suggest that the practice of administering supplemental zinc to patients with cancer with low serum zinc levels needs cautious reconsideration. Close monitoring of zinc levels and consumption in patients and the development of strategies to block ZIP14 could potentially prevent or reverse cachexia development. Our study highlights the possibility of effectively addressing this often overlooked but debilitating side effect of advanced cancer to improve both the survival and quality of life of patients with metastatic cancer.
Methods
Methods, including statements of fig. 6 availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0054-2.
. Human primary skeletal myoblasts were purchased from Lonza. C2C12 and 293 T were purchased from ATCC. C26 and its derivative C26m2, 4T1 and PC9-BrM3 cells were cultured in RPMI (Life Technologies) containing 10% FBS (Sigma) 27, 62, 63 . KP1 cells 61 were cultured in RPMI containing iron supplemented with 10% bovine growth serum (Hyclone). 293 T and C2C12 cells were cultured in DMEM (Life Technologies) containing 10% FBS. Mouse primary myoblasts were cultured in Hams F-10 (Life Technologies) containing 20% FBS and 2.5 ng/ ml of basic fibroblast growth factor (bFGF). All media were supplemented with 1 × penicillin-streptomycin (100 IU/ml of penicillin and 100 µ g/ml of Streptomycin from Life Technologies). Human primary skeletal myoblasts were cultured in SKGM-2 Bullet kit medium (Lonza) following the manufacturer's instructions. Adenoviral infection. C2C12 cells or mouse primary myoblasts were cultured overnight, with 180,000 cells per well in a 6-well plate or in a 35-mm dish. C2C12 cells were infected with either Adeno-Con or Adeno-Zip14 (Vector Biolabs) at a multiplicity of infection (MOI) of 250 using serum-free DMEM containing 8 µ g/ml of polybrene (Sigma) for 4 h. Primary myoblasts were infected with Adeno-Con or Adeno-Zip14 at 50 MOI for 2 h in serum-free Ham's F-10 medium containing 8 µ g/ml of polybrene, which was repeated twice in 24 h. The infected cells were then cultured in their respective culture media described above (see 'Cell culture').
Muscle differentiation assays. Differentiation was initiated after adenoviral infection by switching the growth medium to differentiation medium (DMEM containing 2% horse serum and 5 µ g/ml of insulin for C2C12 cells; DMEM containing 2% horse serum without insulin for primary myoblasts) the day after infection. Differentiation medium was changed every day at the time points indicated in the corresponding figures.
Zinc and MG132 treatment of muscle cells. After 3 d of differentiation, C2C12
cells were cultured with 50 µ M ZnCl 2 in differentiation medium for 24 h. Cells were then used for immunofluorescence staining, gene expression analysis and immunoblot analysis. MG132 treatment was performed as described following Polge et al. 64 : 3-d-differentiated C2C12 cells expressing Zip14 (Adeno-Zip14) were treated with 50 µ M ZnCl 2 for 24 h and then were treated with either vehicle (DMSO) or MG132 (50 µ M) for 3 h before harvest for immunoblot analysis.
Cell viability assay. The viability of C2C12 cells was determined through MTS assay using Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay kit containing the tetrazolium compound, following the manufacturer's instructions. Briefly, 10,000 C2C12 cells infected with Adeno-Con or AdenoZip14 were plated in 100 µ l of growth medium per well in 96-well plates and were differentiated as indicated in the figures. Cells were treated with 50 µ M of ZnCl 2 for 24 h. Cell viability was measured by adding 100 µ l of growth medium without phenol red to each well after aspirating media from the wells. 20 µ l of CellTiter 96 AQueous One Solution Reagent was added to each well. After 1 h of incubation at 37 °C in a CO 2 incubator, the amount of soluble formazan was determined by absorbance at 450 nm. Undifferentiated and differentiated C2C12 cells were collected for an immunoblot analysis that probed for cleaved-caspase-3 expression to assess cell death. C2C12 cells treated with the indicated doses of doxorubicin (doxo; purchased from Sigma) served as a positive control for both types of viability assays.
Treatment with cytokines and signaling pathway inhibitors. Mouse C2C12 myoblasts and human primary skeletal myoblasts were serum-starved overnight and then were treated with or without inhibitors of the TGF-β /SMAD, NF-ĸβ and c-Jun/AP1 pathways, which are SB431542 (Thermo Fisher), CC401 (ThermoFisher) and BAY 11-7085 (Enzo), respectively, followed by treatment with recombinant cytokines purchased from R&D Systems (recombinant mouse TNF-α and TGF-β 1 at 50 ng/ml and 10 ng/ml, respectively, for C2C12; recombinant human TNF-α and TGF-β 1 at 50 ng/ml and 10 ng/ml, respectively, for human primary skeletal myoblasts). In brief, cells were pretreated with either vehicle (DMSO) control, or 10 µ M of the respective pathway inhibitors for 1 h and then were treated with TGF-β 1 for 9 h or TNF-α for 3 h before harvest. Cells with different treatments were harvested together for subsequent analysis.
Zinc uptake assay. 5,000 C2C12 cells expressing either Adeno-Con or Zip14 were cultured in a 96-well plate for 24 h and were washed twice with serum-free and phenol red-free DMEM. Cells were then incubated with 30 µ l of the same DMEM containing 0.5 µ M of ZnCl 2 in 5% CO cell culture incubator at 37 °C. ZnCl 2 levels remaining in the culture medium at 0, 1, 2 and 3 h were determined with FluoZin-3 (Thermo Fisher), a zinc-specific fluorescent chelator 65 . Specifically, 10 µ l of medium was taken out from the plate at the designated time points and mixed with 90 µ l of FluoZin-3 in PBS to give a final FluoZin-3 concentration of 3 µ M. The mixture was incubated for 5 min at room temperature in the dark, and fluorescence was detected by a plate reader (Promega) at Ex 494 nm and Em 516 nm. The linear standard curve of fluorescence signal was determined using ZnCl 2 with known concentrations between 0 to 10 µ M.
Generation and validation of antibodies against human and mouse ZIP14.
Codon-optimized synthetic cDNA fragments (IDT g-Block) encoding the soluble cytoplasmic domain of human (amino acids 246-352) and mouse (amino acids 243-349) ZIP14 were cloned into the pET-28b( + ) vector. Constructs were verified by DNA sequencing and transformed into Rosetta 2(DE3) pLysS cells (Novagen). Protein expression was induced with 1 mM of isopropyl β -d-1-thiogalactopyranoside (IPTG), and protein was purified by fast protein liquid chromatography (FPLC) with a HisTrap HP column (GE Healthcare Life Sciences).
The purity of proteins was tested on 15% SDS-PAGE, indicating that purified ZIP14 domains from mouse and human were > 90% pure. Polyclonal antibodies against both purified human and mouse ZIP14 domains were produced in New Zealand White rabbits at Pacific Immunology Corp. To validate antibodies, western blot was performed on crude bacterial lysates (uninduced and induced) using these immunized sera. Immunized sera against human or mouse ZIP14 only detected ZIP14 domains in the induced crude lysates, confirming antibody specificity. As expected from the high amino acid sequence identity between human and mouse ZIP14 domains, each of these immune sera detected both human and mouse ZIP14 domains by western blot. For immunofluorescence and immunohistochemistry, we purified the IgG fraction from the immunized sera and preimmunized sera from these rabbits by affinity chromatography using HiTrap Protein G column in the FPLC system. The specificity of the purified IgGs was validated by immunohistochemical analyses using liver sections from human patients, Zip14-knockout mice (negative control) and from wild-type Zip14 mice (positive control).
Immunohistochemical staining. Paraffin-embedded tissues were sectioned at 5-µ m thickness. Slides were baked at 60 °C for 1 h and deparaffinized, rehydrated, and treated with 1% hydrogen peroxide for 10 min (except for TGF-β staining, in which tissues were treated with 0.6% hydrogen peroxide in methanol for 1 h 66 ). Antigen retrieval was performed in citrate buffer, pH 6.0 (Vector laboratories) in a steamer with the exception of TGF-β immunostaining, in which 1 mg/ml of hyaluronidase (Sigma) in 0.1 M of sodium acetate buffer, pH 5.5, was used for 30-min digestion at 37 °C. Endogenous avidin-biotin was blocked, and for TGF-β , endogenous mouse IgG was also blocked. After the slides were further blocked with 3% BSA in PBS containing 10% goat serum, tissue sections were incubated with primary antibodies, including rabbit polyclonal antibodies against ZIP14 (1:250, 06-1022 from Millipore; 1:1,000, HPA016508 from Sigma), rabbit polyclonal antibodies against human ZIP14 (1:500) or mouse ZIP14 (1:2,500) developed in our laboratory, rabbit polyclonal antibody against TNF-α (1:100, 210-401-321 from Rockland), and mouse monoclonal antibody against TGF-β (15 µ g/ml, clone 1D11.16.8 from BioXCell), which were followed by corresponding biotinylated secondary antibodies. Secondary antibodies include biotinylated goat anti-rabbit IgG (1:250, Vector laboratories, BA1000) and biotinylated goat anti-mouse IgG (1:250, Vector laboratories, MOM Basic kit, BMK-2202). The ABC kit and the DAB kit (Vector laboratories) were used for detection, following the manufacturer's instructions. Sections were subsequently counterstained with hematoxylin and then were dehydrated and mounted using Cryoseal XYL (Richard-Allan Scientific) for subsequent histological analysis.
Mouse studies. Treatment of mice was in accordance with the institutional guidelines of Columbia University Institute of Comparative Medicine and approved by The Columbia University Institutional Animal Care and Use Committee (IACUC). All animal experiments were conducted in compliance with relevant ethical regulations. Mice were housed in the animal facility at Columbia University Medical Center (CUMC) under conventional conditions with constant temperature and humidity. Mice were fed a standard diet (LabDiet 5053). Balb/c and C57Bl/6 mice were obtained from Jackson Laboratories. Athymic nude, DBA/2 and 129P2/Ola mice were obtained from Envigo. Zip14-knockout mice generated by Hojyo and Fukada laboratory 33 and were obtained on a congenic Balb/c background from the Knutson Laboratory 67 (University of Florida). Balb/c mice were used for 4T1 mouse breast cancer cell line implantation; C57Bl/6 mice were crossed with 129P2/Ola mice to generate 129P2/Ola × C57Bl/6 mice for KP1 cell line implantation; Balb/c mice were crossed with DBA/2 mice to generate CD2F1 mice for C26 and C26m2 implantation. Zip14-knockout mice in the Balb/c background were crossed with DBA/2 mice to generate Zip14-knockout mice in the CD2F1 background. Genotyping for all the strains was performed using the primers listed in Supplementary Table 6 . Mice were weighed weekly. Food and water intake was measured by weighing food and measuring water in a graduated cylinder weekly. Mouse body condition as a measure of cachexia was assessed using a body-condition scoring system as previously reported 68 . Metastasis assays in mice. Both male and female mice were used in this study. Athymic mice aged 8-9 weeks were injected with 1 × 10 5 PC9-BrM3 cells via the intracardiac route into arterial circulation for the experimental metastasis assays. For tumor studies, mice aged between 5 and 6 weeks for C26m2, 8 and 9 weeks for 4T1 and 4 and 5 weeks for KP1 injections were used. For each model, 1 × 10 6 tumor cells were subcutaneously injected in the right flanks of syngeneic mice as previously described. Subcutaneous tumor was removed between 2 and 3 weeks to allow for metastasis formation following the tumor-resection-relapse approach 20 . In brief, for tumor resection, mice were anesthetized with isoflurane (3-4%) administered with a precision vaporizer, and any large veins were cauterized. Buprenorphine (0.05 mg/kg) was given subcutaneously every 6-12 h for 48 h for pain relief after surgery. Wild-type Zip14 or Zip14-knockout mice in the CD2F1 or Balb/c background at 4-5 weeks of age were subcutaneously injected with 1 × 10 6 C26m2 or 4T1 tumor cells, respectively. Tumors were not resected with survival-surgeries in the wild-type Zip14 and Zip14-knockout mice owing to the phenotypic and behavioral abnormalities in the Zip14-knockout mice. Spontaneous metastasis was monitored via bioluminescent imaging in the wild-type Zip14 and Zip14-knockout groups at endpoint (5 weeks following injection of C26m2 or 4T1 tumor cells, respectively) and was confirmed by histology upon harvest.
Adenoviral delivery of
Neutralization assays. Athymic nude mice and Balb/c mice that were 8-9 weeks of age were subcutaneously injected 45 with C26m2 and 4T1 cells, respectively. Mice were randomized for treatment group assignments. Tumors were surgically removed 2-3 weeks after tumor cell injection. One week after tumor removal, InVivoPlus anti-TGF-β (BP0057, Clone: 1D11.16.8), InVivoPlus anti-TNF-α (BP0058, Clone: XT3.11) or InVivoPlus Mouse IgG1 Isotype control (BP0083, Clone: MOPC-21) from BioXCell were intraperitoneally injected into the mice at a dosage of 200 µ g/mouse three times per week for 1 week.
Tissue collection. After euthanasia, tibialis anterior, gastrocnemius, quadriceps, soleus, EDL, heart and diaphragm muscles, livers and lungs were collected for histology or were snap frozen for molecular analysis. Metastatic tumors were collected in formalin for histological analysis, and a part of the C26 metastases was used for derivation of cell lines for C26m2. For cell derivation, tumors were dissociated in 3 mg/ml of Collagenase I (Worthington Biochemical Corp.) and 2 U/ml of Dispase II (Roche) for 1 h at 37 °C with gentle rocking and then were filtered through a 70-µ m mesh. Cells were briefly centrifuged (300g), resuspended in culture medium and grown to confluence.
Generation of stable cell lines expressing luciferase. All cancer cell lines used in this study were stably infected with lentivirus expressing luciferase enzyme and hygromycin resistance marker. Briefly, cells were plated at 30% confluency (adherent cells) or at a density of 1 × 10 5 /ml (suspension cells). Lentivirus was produced using pLVX-Hygro vector expressing luciferase gene (a kind gift from Z. Granot, Hebrew University of Jerusalem). Target cells were transduced with the viral supernatant for 3 h. After 48 h following infection, stable cells integrated with the vector were selected using 100 µ g/ml of hygromycin B (Invitrogen) for 1 week.
Bioluminescence and fluorescence by in vivo imaging. Tumor growth was measured using digital calipers, and spontaneous metastasis was monitored by bioluminescent imaging using the In Vivo Imaging System (IVIS) (Perkin Elmer). Briefly, mice were anesthetized with 3-4% isoflurane and injected with 150 ng of D-Luciferin (Fisher Scientific) via intraperitoneal injections. Also, pigmented mice were shaved before imaging. The mice were then placed inside the PerkinElmer IVIS Spectrum Optical Imaging System and scanned for 1 min to measure bioluminescence or fluorescence for mCherry imaging.
Zinc-supplemented water treatment for mice. ZnSO 4 solution was purchased from Sigma. Wild-type Zip14 and Zip14-knockout mice were given either regular water or zinc-supplemented drinking water (25 mM ZnSO 4 in drinking water, as described 70 ). Zinc water was started from the day of tumor injection in the tumor-bearing group and in matched uninjected controls, which continued until the animals were euthanized at 15 d. Tumors were not resected because cachectic symptoms started to develop early and were visible between 8 and 10 d in the tumor-bearing Zip14-WT group of mice on zinc-enriched water.
Behavioral coordination tests in mice. Rotamex-5 (Columbus Instruments), with a rod diameter of 3 cm, was used for testing coordination in mice. In this setup, automatic fall detection is implemented within each lane by a series of photocells placed above the rotating rod. The speed of the rotating rod is programmed for either constant or accelerated modes. Rod speed can be specified in either terms of rotations (r.p.m.) or in linear terms (cm per s). Latency to fall is detected with 0.1 s temporal resolution. Rate of rotation at time of fall is resolved to 0.1 r.p.m. or 0.1 cm/s. Both latency and rod speed at time of fall are presented on a display for each of the four lanes. In brief, following the manufacturer's instructions, for each mouse, an average of three runs are recorded with a 5-min rest between each run. The speed the rod is spinning at when the mouse falls is measured in r.p.m. The time it takes for the mouse to fall is measured in seconds. Mice are placed on the rod for 1 min while the rod spins at 1 r.p.m. so the mouse gets habituated to the rod spinning. When the experiment begins, the rod accelerates at 1 r.p.m. every 10 s until the mouse falls off. When the mouse falls off, the latency to fall (seconds) is measured.
Virus production, purification and titration. For AAV production, we constructed two different AAV vectors, including AAV-CAG-ZIP14-IRES-GFP and AAV-CAG-mCherry. pAAV-Ef1a-mCherry-IRES-Cre (Addgene plasmid no. 55632) was a gift from K. Deisseroth and was used as a PCR template for cloning mCherry and IRES. AAV-CAG-ChR2-GFP (Addgene plasmid no. 26929) was a gift from E. Boyden and was used as a template for cloning GFP. AAV-CAGChR2-GFP was also used as a backbone AAV vector with CAG promoter after digestion by BamHI (Roche) and BsrGI (Thermo Fisher). Through sequential PCR amplification, mCherry alone and ZIP14-IRES-GFP amplicons, containing N-terminal BamHI and C-terminal BsrGI digestion sites, were introduced into the digested AAV-CAG backbone to construct the AAV vectors. The AAV constructs were confirmed by sequencing and then were cotransfected with pDeltaF6 and AAV2/9 Helper plasmids, in a ratio of 1:2:1.6, into 293 T cells by the calciumphosphate transfection method. Forty-eight hours later, 293 T cells containing AAV were collected for virus purification.
Viruses were purified following the protocol as described before 71 . Briefly, AAV9-producing 293 T cells were detached by adding 1/80 volume of 0.5 M EDTA (pH 8.0) for 10 min incubation at room temperature and were collected by centrifugation (2,000 g) for 10 min at 4 °C. Cell pellets were lysed by adding 24 ml of 0.5% Triton X-100 in PBS containing 5 µ g/ml of RNase A (Sigma) and shaking for 1 h at 37 °C. Cell lysates were centrifuged at 10,000 g for 10 min at 4 °C, and 24 ml of supernatant was added into an ultracentrifuge tube. The virus solution was raised up by successive addition of 3 ml of 25% iodixanol, 4 ml of 40% iodixanol and 2 ml of 60% iodixanol to the bottom of the tube. All the iodixanol solutions were prepared in PBS containing 1 M NaCl, 1 mM MgCl 2 and 2.5 mM KCl. The tube was centrifuged at 350,000 g for 1.5 h at 18 °C. 4.5 ml of virus solution at the bottom of the tube was collected using an 18-gauge needle and filtered through a 0.45-µ m filter. Virus solution was then concentrated using Amicon Ultra-15 (100 K) (Millipore) and washed three times with 250 mM NaCl solution. Virus titration was performed with primers targeting CAG (forward, 5′ -TTACGGTAAACTGCCCACTTG-3′ ; reverse, 5′ -CATAAGGTCATGTACTGGGCATAA-3′ ) with AAV-CAG-mCherry plasmid as standard.
AAV9 injection. AAV9-mCherry-U6-mSLC39A14-shRNA and AAV9-mCherry-U6-scrmb-shRNA, both from Vector Biolabs, were used for knockdown of Zip14 expression and as negative control, respectively, through direct injection into gastrocnemius muscles of mice. The validated shRNA sequence for knockdown of Zip14 is CCGG-GCAGGCTCTCTTCTTCAACTTCTCGCGAAGTTGAAGA AGAAGAGAGCCTGC-TTTTTG (Vector Biolabs). Zip14 knockdown efficiency was about 90% in Hepa1.6 cells (Vector Biolabs). For knockdown of Zip14 in mouse skeletal muscle, 3 × 10 11 genome copies of AAV9 virus were directly injected into the right gastrocnemius muscle using five injection sites in 7-to 8-week-old athymic mice. mCherry expression was monitored weekly by fluorescence imaging, and after confirmation, tumor growth and metastasis assays were performed. Athymic mice were used to avoid additional immune reaction. For overexpression of Zip14, the 2.2 × 10 10 genome copies of AAV9 virus purified (described above) were injected into the gastrocnemius muscle using five injection sites in 5-to 6-week-old Balb/c Zip14-knockout mice.
Functional assays of grip strength. Grip strength was measured in mice injected with 4T1 or C26m2 cells or age-matched non-tumor-bearing controls using a Digital Grip Strength Meter (Columbus Instruments). A minimum of five measurements were taken from each mouse for hind limb measurements. In both groups, grip strength was calculated as the average of the five measurements divided by body weight for each mouse.
Measurement of zinc metal ion in mouse muscles.
Muscles were analyzed at the the Diagnostic Center for Population & Animal Health at Michigan State University. Briefly, tissues were dried overnight in a 75 °C oven and then digested overnight in approximately 10 × the dry tissue mass of nitric acid. The digested samples were diluted with water to 100 × the dried tissue mass. Elemental analysis Articles NaTuRe MedICINe was performed using an Agilent Inductively Coupled-Plasma Mass Spectrometer. Elemental concentrations were calibrated using a 4-point linear curve of the analyte-internal standard response ratio. Standards were from Inorganic Ventures.
Single myofiber isolation and LA-ICP-MS. Single myofiber isolation from EDL muscles was performed following the protocol described before 72 . Briefly, EDL muscles were dissected and transferred into a prewarmed horse-serum-coated Petri dish containing 1.8 ml DMEM supplemented with 10% FBS, 1 × penicillinstreptomycin antibiotics and 0.11 mg/ml of sodium pyruvate. Then, 0.2 ml of 2% collagenase (about 40,000 U/ml) solution was added, and muscles were digested at 37 °C in a 5% CO 2 incubator for 40-60 min, during which a large bore glass pipette for flushing the muscle was used to loosen up the muscle and release single fibers into medium. The released muscle myofibers were transferred into a prewarmed horse-serum-coated Petri dish with 4 ml of DMEM containing 10% FBS and 0.11 mg sodium pyruvate to avoid overdigestion. The myofibers were then transferred into a prewarmed horse-serum-coated Petri dish containing wash medium (DMEM supplemented with 1 × penicllin-streptomycin and 0.11 mg/ml of sodium pyruvate) and washed three times to remove dead myofibers and debris. Single myofibers were transferred onto a glass slide and air dried. For subsequent LA-ICP-MS analysis, a single muscle fiber mounted on a slide was placed in a sealed ablation cell and ablated with a new wave UP213 Nd:YAG laser beam at 0.25-0.35 mJ with a 100-µ m spot size. Ablation was set at 5 µ m/sec and 20 Hz. The ablated sample particles were then transferred to a Thermo iCapQ ICP-MS that was optimized using a NIST 612 glass standard before every sample run. The isotopes selected for analysis were 64 Zn, 66 Zn and 31 P. Individual muscle fiber data were subtracted from a blank line on the same slide with the same dimension, size and parameters as the sample line.
Liver and kidney function analysis. Liver and kidney function tests were performed using automated clinical chemistry analyzer (VetAce Clinical Chemistry System; Alfa Wasserman Diagnostic LLC, West Caldwell, New Jersey) for aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine in serum, following the manufacturer's instructions. Specifically, 20 µ l, 3 µ l and 20 µ l of serum from mice bearing C26m2 metastases with or without zinc supplemented water treatment were used for assays of AST, BUN and creatinine, respectively.
Muscle diameter analysis.
Images of muscle sections stained with H&E or laminin were taken at 20 × magnification. Fiber diameters were quantified using ImageJ software as described before 62 from a minimum of 500 fibers per 5 randomly chosen fields for each mouse, at a minimum of 3 mice per group. For morphometric analysis, the percentage of fiber number in each predefined group was categorized by fiber diameter from mice bearing 4T1 or C26m2 metastases and their respective controls. skeletal muscle satellite cells were isolated according to the methods described previously 35, 73 . Briefly, all limb skeletal muscles from 1-to 2-week-old mice were combined and minced into a smooth pulp. The muscles were then digested with collagenase (2-5 ml of 0.2% collagenase type 2, based upon muscle mass, in DMEM with 10% FBS) at 37 °C for 40 min. The dissociated single cells were filtered through a 70-µ m strainer and pelleted by centrifugation at 400 g for 5 min at 4 °C. Cells were washed twice with DMEM containing 2% FBS and were suspended in 200-500 µ l of DMEM with 2% FBS. Fc blocker (1:100, BD Pharmingen, 553142) was added to the cell suspension, which was incubated on ice for 10 min. The following antibodies were then added into the cell suspension: CD31-PE (1:100, eBioscience, 12-0311-81), CD45-PE (1:100, eBioscience, 12-0451-83), SCA-1-PE (1:100, eBioscience, 12-5981-81), INT-α 7 antibody (1:10, Miltenyi Biotec, 130-103-774). The suspension was then gently rocked at 4 °C for 15 min. Cell pellet was washed twice with DMEM containing 2% FBS and was resuspended in DMEM with 2% FBS. 40-100 µ l of anti-PE magnetic beads (Miltenyi Biotec, 130-105-639) was added into the cell suspension, which was gently rocked at 4 °C for 15 min. Cell pellet was washed twice with MACS buffer (PBS with 0.5% BSA and 2 mM EDTA), resuspended with 0.5 ml of MACS buffer and applied onto a LD column that was set up on a magnetic board (Miltenyi Biotech). The flow-through cells were collected according to the manufacturer's protocol and were pelleted by centrifugation (400g). The cells were then resuspended with 80-200 µ l of DMEM with 2% FBS, and 20-50 µ l of anti-mouse IgG magnetic beads (Miltenyi Biotec, 130-048-402) was added into the cell suspension, which was gently rocked at 4 °C for 15 min, and then the cell pellet was washed twice with MACS buffer. Cells were then resuspended with 0.5 ml of MACS buffer and applied onto an LS column. After washing with MACS buffer, the cells retained in the LS column were collected according to the manufacturer's protocol. Isolated muscle satellite cells were cultured in collagen-coated dishes with myoblast growth medium as described 73 .
Isolation of muscle progenitor cells by flow cytometry. Mouse gastrocnemius muscles were collected and processed for depletion of CD45 + and CD31 + cells with anti-PE magnetic beads using LD column (Miltenyi Biotech) as described (see 'Magnetic Sorting of Muscle Satellite Cells'). Cells in the flow-through fraction were pelleted by centrifugation (400g) and resuspended with 100 µ l of DMEM containing 2% FBS. The following antibodies were then added into the cell suspension: CD34-FITC ( RNA extraction for RNA-seq and qRT-PCR. Total RNA was extracted using TRIzol reagent (Thermo Fisher) as previously described 74 . RNA was further purified using RNeasy Mini kit including a DNase digest following the manufacturer's instructions (Qiagen). RNA was quantified using Nanodrop (Thermo Scientific), and RNA quality was assessed by capillary gel electrophoresis (Agilent 2100 Bioanalyzer; Agilent Technologies, Inc.). Single-end cDNA libraries were prepared for each sample and sequenced using the Illumina TruSeq RNA Sample Preparation Kit following the manufacturer's procedures and were sequenced using the Illumina HiSeq 2000. Library construction and RNA-seq were performed in the Columbia Genome Center at CUIMC.
For qRT-RCR analysis, 100-500 ng of total RNA was used for cDNA synthesis using the transcriptor first-strand cDNA synthesis kit (Roche) following the manufacturer's instructions. 10 ng of cDNA was used for qRT-RCR reactions using SYBR Green or TaqMan PCR master mix (Applied Biosystems) with gene-specific primers. qRT-PCR was run on Applied Biosystems 7500 fast real-time PCR system and analyzed by Applied Biosystems software. GAPDH or B2M was used as an internal control when qRT-PCR was performed using SYBR Green or TaqMan PCR master mix, respectively; except for 18 s was used as internal control in gene expression analysis of isolated muscle progenitor cells. The normalized fold change of gene expression level was analyzed using the 2 -∆∆Ct method 75 . SYBR Green realtime PCR primer sequences are listed in Supplementary Table 7 . TaqMan real-time PCR primers are: B2M (Hs99999907_m1) and CXCL1 (Hs00236937_m1) from Applied Biosystems.
Human samples. Human tissues were obtained upon autopsy at New York Presbyterian/Columbia University Medical Center or from the Rapid Autopsy Pancreas Program at the University of Nebraska Medical Center with institutional review board (IRB)-approved protocols from both institutions. All research was conducted in compliance with ethical regulations. In particular, human psoas muscles fixed in 10% buffered formalin were collected from patients with metastatic cancer at New York Presbyterian/Columbia University Medical Center upon autopsy or from the Rapid Autopsy Pancreas Program at the University of Nebraska Medical Center. To ensure minimal degradation of tissues, muscles collected at the Rapid Autopsy Program were harvested within 2-3 h post mortem, and the specimens were fixed in formalin immediately after collection. Presence of cancer and cachexia were determined on the basis of the autopsy report and were additionally confirmed through histological analysis by two independent pathologists at the University of Nebraska Medical Center and Columbia University Medical Center. Descriptions of cancer type and presence of cachexia are listed in Supplementary Table 3 .
Subcellular fractionation of differentiated C2C12 muscle cells. Fractionation of soluble and myofibrillar components was performed following the protocol described before 76 . In brief, differentiated C2C12 muscle cells were collected in cold lysis buffer (20 mM of Tris-HCl pH 7.2, 5 mM of EGTA, 100 mM of KCl, 1%Triton X-100, and 1 × protease and phosphatase inhibitor cocktail) and lysed by gentle agitation at 4 °C for 1 h. After centrifugation at 3,000 g for 30 min at 4 °C, the cytosolic fraction (supernatant) was collected and stored -at -80 °C. The pellet (myofibrils) was washed twice with wash buffer (20 mM of Tris-HCl, pH 7.2, 100 mM of KCl, and 1 mM of DTT). After centrifugation at 3,000 g for 10 min at 4 °C, myofibrillar fraction was extracted in ice-cold extraction buffer (0.6 M of KCl, 1% Triton X-100, 2 mM of EDTA, 1 mM of DTT and 1 × protease and phosphatase inhibitor cocktail) with shaking at 4 °C. The purified myofibrillar fraction was collected after centrifugation for 3,000 g at 4 °C and was stored -at -80 °C until further use.
Immunofluorescence staining and immunoblotting. For immunofluorescence staining of cultured cells, cells were fixed with 2% formaldehyde for 30 min, permeabilized with 0.5% NP-40 for 5 min, and blocked with 10% goat serum in PBS containing 3% BSA for 30 min. Cells were then incubated for 1 h with primary antibody: rabbit polyclonal antibodies against mouse ZIP14 (1:500, developed in our laboratory), Desmin (1:500 Sigma, D8281), mouse monoclonal antibodies against fast MyHC (1:500 Sigma, clone MY-32) or tropomyosin (1:500 DSHB, CH1) followed by 30-min incubation with AlexaFluor 568-labeled secondary antibody (Thermo Fisher, A11031 for goat anti-mouse IgG Alexa Fluor 568 or A11011 for goat anti-rabbit IgG Alexa Fluor 568). Slides were then mounted using Fluoro-gel II with DAPI (Electron Microscopy Sciences). For immunofluorescence staining of mouse muscle tissues with ZIP14, cryosections of 5-µ m thickness were air dried for 1 h and fixed with 2% PFA in PBS for 10 min at room temperature and then were washed twice with PBS containing 0.2% Tween-20. PFA neutralization was performed using 1% glycine in PBS for 15 min, and sections were permeabilized for 15 min using 1% Triton X-100 in PBS. The sections were treated with 1% H 2 O 2 for 10 min and were sequentially blocked by avidin-biotin blocking kit and 3% BSA in PBS containing 10% goat serum, followed by 30 min incubation of rabbit polyclonal antibody against mouse ZIP14 (1:1,000, developed in our laboratory). Sections were then incubated with a biotinylated secondary antibody (1:250, Vector Laboratories, BA1000), which was followed by 30-min incubation with HRP-conjugated streptavidin (PerkinElmer). Signal amplification was performed using biotin-tyramide kit (TSA Biotin System, PerkinElmer), following the manufacturer's instructions. The sections were subsequently incubated with AlexaFluor 647-conjugated streptavidin (Jackson Laboratories, 016-600-084) for 30 min and then were mounted using Fluoro-gel II with DAPI. For immunofluorescence staining of tissues with Laminin and CD31, the cryosections were air dried for approximately 10 min and fixed with cold acetone for 10 min and then washed with PBS. Sections were blocked with 3% BSA in PBS containing 10% goat serum for 1 h at room temperature and then incubated with rabbit polyclonal antibody against Laminin (1:200) (Sigma, L9393) and/or rat monoclonal antibody against CD31 (BD, 557355) for 30 min at room temperature. After washing with PBS, the sections were then incubated with AlexaFluor 488 and/or 568 secondary antibody (Thermo Fisher, A11034 for goat anti-rabbit IgG Alexa Fluor 488 and A11077 for Goat anti-rat IgG Alexa Fluor 568) for 30 min at room temperature and were mounted with Fluoro-gel II with DAPI. For immunofluorescence staining of myosin isoforms in muscle, cryosections were blocked with 3% BSA in PBS containing 10% goat serum, followed by 30-min incubation with primary monoclonal antibodies (1:1 of MyHC IIa (DSHB, SC-71) and MyHC IIb (DSHB, BF-F3), which are mouse IgG1 and IgM isotypes, respectively). After another 30-min incubation with a mixture of secondary antibodies (1:500 each of goat anti-mouse IgG1 Alexa 488 and goat anti-mouse IgM Alexa 546, all from Thermo Fisher, A21121 and A21045), the sections were washed and mounted using Fluorogel II with DAPI. For immunofluorescence staining of PAX7 and ZIP14 on muscle tissues from patients with cancer, paraffin-embedded tissues were sectioned at 5-µ m thickness, and the slides were deparaffinized and rehydrated as described above. The muscle sections were blocked with 3% BSA in PBS containing 10% goat serum for 30 min at room temperature and then incubated with rabbit polyclonal antibody against human ZIP14 (1:500, developed in our laboratory) and mouse monoclonal antibody against PAX7 (1;200, IgG1 from DSHB) for 30 min at room temperature. After washing with PBS, the sections were then incubated with goat anti-rabbit Alexa Fluor 568 and goat anti-mouse IgG1 Alexa Fluor 488 secondary antibodies (Thermo Fisher, A11011 and A21121) for 30 min at room temperature and mounted with Fluoro-gel II with DAPI.
For immunoblot analysis, cells or muscle tissues were lysed or homogenized in the indicated lysis buffers as described before 45, 76, 77 . High-salt lysis buffer was used for greater solubility of myofibrillar proteins such as myosin 42, 77 , which is composed of 300 mM of NaCl, 0.1 M of NaH2PO4, 0.05 M of Na 2 HPO 4 , 0.01 M of Na 4 P 2 O 7 , 1 mM of MgCl 2 , 10 mM of EDTA, 1 mM of DTT (pH 6.5), and low-salt lysis buffer composed of 50 mM of Tris-HCl pH 7.5, 150 mM of NaCl, 0.5% of TritonX-100, and 1 mM of EDTA was used for immunoblot analysis of other nonmyofibrillar proteins. Both the high-and low-salt lysis buffers were supplemented with protease inhibitor and phosphatase inhibitor cocktail (Thermo Scientific). Protein concentration was determined by Pierce BCA protein assay kit (Thermo scientific), and proteins were resolved by SDS-PAGE and transferred onto Polyvinylidene difluoride membranes. After blocking with 5% wt/vol nonfat milk in TBS-T (20 mM of Tris-HCl pH 7.4, 500 mM of NaCl and 0.1% of Tween 20) for 1 h at room temperature, the membranes were incubated with the following antibodies: rabbit polyclonal antibodies against ZIP14 (1:1,000) (Millipore, 06-1022, NRG1830910), phosphorylated c-Jun (p-c-Jun) (S63) (1:1,000) (Cell Signaling, no. 9261) and cleaved-caspase-3 (1:1,000) (Cell Signaling, no. 9661); rabbit monoclonal antibodies against p-p65 (S536) (no. 3033), p65 (no. 8242), c-Jun (no. 9165), p-SMAD2 (S465/467) (no. 3108), SMAD2 (no. 5339) purchased from Cell Signaling with a dilution of 1:1,000; mouse monoclonal antibodies against fast MyHC (1:5,000) (Sigma, clone MY-32), skeletal actin (1:5,000) (Sigma, A2172), tubulin (1:5,000) (Sigma, T6074), troponin T (1:1,000) (DSHB, JLT12), MyLC (1:1,000) (DSHB, F310) and tropomyosin (1:1,000) (DSHB, CH1). The membranes were then incubated with corresponding HRP-conjugated secondary antibodies, developed using ECL substrate (Bio-Rad) and visualized using the BioRad ChemiDoc Touch Imaging System. Succinate dehydrogenase staining of mouse muscles. Cryosections of mouse muscles were incubated with 1 mg/ml of nitrotetrazolium blue chloride and 100 mM of sodium succinate in PBS at 37 °C for 30 min. Slides were washed three times with PBS and mounted with glycerol.
Computational analysis. From RNA-seq data, reads were generated using RTA (Illumina) for base calling, and bcl2fastq (version 1.8.4) was used for converting BCL to fastq format, coupled with adaptor trimming. Reads were mapped to a reference genome (Mouse: NCBIm37) using Tophat2 (version 2.0.11) with very-fast (-D 5 -R 1 -N 0 -L 22 -i S,0,2.50) option resulting in zero 0 (N) mismatches. Reads across junctions were checked and indicated in the supplied GFF (-no-novel-juncs). Bam files obtained from TopHat were used to generate the differential gene using the module Cuffdiff (Cufflinks 2.2.1) with default settings and were sorted on the basis of the FDR or q value. The cutoff for the differential gene list was set as q < 0.05. The expression values obtained using Cuffdiff were checked for data quality using the PCA module of R package CummeRbund 2.20.0. From the differential gene lists of RNA-seq of muscles from C26m2 and 4T1 models, a new list was created with shared genes from both the models. To prevent spurious results from infinity values, genes with low expression on one condition and/or zero expression on another were excluded from the initial analysis using C26m2 as the base model. GSEA using the GSEAPreranked tool for RNA-seq data was used for conducting the analysis, where fold change values was used as our criteria for ranking. Preranked GSEA was performed on standalone GSEA (v2.2.2) using the C2_CP_KEGG geneset and the HALLMARK_MYOGENESIS genesets 78, 79 . Functional annotation clustering of the common genes was performed using DAVID from https:// david.ncifcrf.gov/. Upregulated genes (log 2 (fold change) > 1 with P and q values < 0.05) or downregulated genes (log 2 (fold change) < -1 with P and q values < 0.05) were used for DAVID analysis. Clusters with an ES ≥ 5.0 and a significant P < 0.05 were analyzed. IPA Upstream Regulator Analysis (Ingenuity, Qiagen) was performed using the RNA-seq experimental dataset to identify upstream regulators and to predict whether they were activated or inhibited. IPA analysis was performed using the 1,297 shared genes between C26m2 and 4T1 with a fold-change > 1.5 with significant P and q values < 0.05. For heat map representation of qRT-PCR data, heat maps were created using the gplots library in R for percentage value relative to control.
Statistical analysis. Statistical significance was determined by unpaired twotailed Student's t-test, two sided Welch's t-test, Pearson Chi-square test or one-way ANOVA with post hoc Tukey's test using Prism 6 software (GraphPad Software). All values are mean ± s.e.m., and a P value < 0.05 was considered statistically significant. Specifically, for analysis using DAVID, P values from the one-tailed Fisher's exact test were used as cutoff criteria. P values were further corrected using the Benjamini-Hochberg procedure. For processing of RNA-seq data using Cuffdiff, the P values were obtained using JensenShannon divergence statistics. For multiple-testing correction, q values are obtained using the Benjamini-Hochberg approach for controlling FDR. For IPA, P values from Fisher's exact test were used and corrected using the BenjaminiHochberg procedure. For gene-set enrichment analysis, a modified form of the Kolmogorov-Smirnov test was used for calculating ES. The nominal P values generated were further corrected for FDR.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
Supplementary information and source data files are available in the online version of the paper or can be obtained from corresponding author upon request. The uncropped immunoblot images used in the main figures are shown in Supplementary Fig. 6 . The RNA-seq data was deposited in the Gene Expression Omnibus (GEO) with accession number GSE112204. Deidentified patient information with relevant clinical annotation is available in Supplementary  Table 3 
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